INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
Status: Active_not_recruiting
Location: See location...
Study Type: Observational
SUMMARY
The INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to look at other potential biomarkers of metastatic relapse such as Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a tumor RNA signature.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Female
• Age \> 18 years
• Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer
• Patient able to understand the French language
• Patient affiliated to social security
• Obtaining signed written consent
Locations
Other Locations
France
Centre Jean PERRIN
Clermont-ferrand
Time Frame
Start Date: 2020-11-27
Completion Date: 2029-11-09
Participants
Target number of participants: 90
Authors
Related Therapeutic Areas
Sponsors
Leads: Centre Jean Perrin